Patients continue to benefit from high-dose atorvastatin therapy for at least 5 years after acute coronary syndrome, according to a new study.
Many patients with Parkinson's disease do not receive treatment for their depressive symptoms.
Ebola-related death toll climbs above 1200 as health care workers face increased threats from desperate region.
Mylan, Inc, has launched a therapeutically equivalent version of Precedex, while Hospira, Inc, has filed a lawsuit to challenge the generic approval.
Grocery store chain joins growing list of major companies offering enhanced specialty pharmacy.
Curcumin, a component of the traditional Indian spice, turmeric, is highly effective in combating the symptoms of major depressive disorder.
The FDA has approved peginterferon beta-1a (Plegridy), a groundbreaking injectable therapy for patients with relapsing forms of multiple sclerosis.